Skip to content

Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy

Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02445235
Acronym
SOPWS
Enrollment
88
Registered
2015-05-15
Start date
2015-04-30
Completion date
2016-01-31
Last updated
2016-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Fungal Infection

Keywords

pain, wound care, fungal infections, scars, chronic pain, outcomes, PRO

Brief summary

This observational study is designed to evaluate the reported outcomes for patients receiving topical therapy for the treatment of pain, fungal infections or skin scars. The patients will complete the Patient Reported Outcome (PRO) survey monthly and provide valuable data on the patients perception of their health status and well being while receiving therapy.

Detailed description

This observational study is designed to evaluate the reported outcomes for patients receiving topical therapy for the treatment of pain, fungal infections or skin scars. The patients will complete the Patient Reported Outcome (PRO) survey monthly and provide valuable data on the patients perception of their health status and well being while receiving therapy. Patients are enrolled for 18 months. The investigator will complete a global patient assessment monthly of the patient's condition.

Interventions

OTHERPatient Reported Outcome Survey Tool

Patient Reported Outcome Survey Tool

Sponsors

IFG Medical
CollaboratorINDUSTRY
Bracane Company
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. An 18 to 85 years old (inclusive) female or male patient 2. Prescribed compound for the treatment of pain, wound healing or surface skin scar by their Principal Investigator 3. Any systemic disease (cardiac, renal, or hepatic) must be well controlled. 4. Has no skin lesions at the site of application of study medication except for wound under treatment 5. Able to provide informed consent

Exclusion criteria

1. Pregnant or lactating females or women at the child bearing potential not using effective contraception. 2. Use of other topical or transdermal medication. Patients may be withdrawn for a period of 2 weeks from all topical or transdermal medications prior to study initiation. 3. Hypersensitivity to local anesthetic or other ingredients of the compounded creams to be used in a study. 4. Prior reconstruction skin surgery or skin grafts in the area of cream application preventing absorption of cream except for the treatment of surface skin scar 5. Chronic pain conditions not expected to respond to topical pain medication such as deep abdominal pain, or from conditions such as cancer, or gouty arthritis.

Design outcomes

Primary

MeasureTime frame
Change in Baseline PRO and Health Status PerceptionUp to eighteen (18) months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026